Drug InfoNet.com
DrugInfoNet Home Page FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Actos

[Pioglitazone]

Ethnicity:

Pharmacokinetic data among various ethnic groups are not available.

Drug-Drug Interactions

Text Continues Below



The following drugs were studied in healthy volunteers with a co-administration of ACTOS 45 mg once daily. Listed below are the results:

Fexofenadine HCI:
Co-administration of ACTOS for 7 days with 60 mg fexofenadine administered orally twice daily resulted in no significant effect on pioglitazone pharmaco-kinetics. ACTOS had no significant effect on fexofenadine pharmacokinetics.

Glipizide:
Co-administration of ACTOS and 5 mg glipizide administered orally once daily for 7 days did not alter the steady-state pharmacokinetics of glipizide.

Digoxin:
Co-administration of ACTOS with 0.25 mg digoxin administered orally once daily 7 days did not alter the steady-state pharmacokinetics of digoxin.

Warfarin:
Co-administration of ACTOS for 7 days with warfarin did not alter the steady-state pharmacokinetics of warfarin. ACTOS has no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin therapy.

Metformin:
Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.

Midazolam:
Administration of ACTOS for 15 days followed by a single 7.5 mg dose of midazolam syrup resulted in a 26% reduction in midazolam Cmax and AUC.

Ranitidine HCI:
Co-administration of ACTOS for 7 days with ranitidine administered orally twice daily for either 4 or 7 days resulted in no significant effect on pioglitazone pharmacokinetics. ACTOS showed no significant effect on ranitidine pharmacokinetics. ER: Co-administration of ACTOS for 7 days with 30 mg nifedipine ER adminis-tered orally once daily for 4 days to male and female volunteers resulted in least square mean (90% Cl) values for unchanged nifedipine of 0.83 (0.73-0.95) for Cmax and 0.88 (0.80-0.96) for AUC. In view of the high variability of nifedipine pharmacokinetics, the clinical significance of this finding is unknown.

Page:  << Prev | 1 | 2 | 3 | 4 | 5 | Next >>







New Features

New ADHD Site!


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service    

FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Contact | Site Map | Search | Disclaimer | Mission Statement

© 1996-2003 DRUG INFONET, Inc. All rights reserved.